Western blot assay. The protein expression of MTA1 (81 kDa) was evaluated in two normal human cell lines HUVEC and Het-1A and human breast cancer cell lines MCF-7. In brief, The cells were collected and lysed using RIPA buffer (APPLYGEN, China); the protein concentrations of the resulting lysates were normalized, and 30 μg protein from each cell were added to different lanes of the SDS-PAGE gel (10%) and transferred to the PVDF membrane (BIO-RAD, USA). Membranes were blocked with 5% skim milk in TBST buffer (50 mM Tris-HCl, 0.1% Tween-20, pH7.4) for about 1.5 h. Then wash the membranes three times for 5min with TBST. Further, the membranes were incubated overnight at 4℃ with the indicated primary antibody:
HLA-DRB1. Peptides with IC 50 below 500 nM are defined as weak binders; those with IC 50 below 50 nM as strong binders. Table S1 : Prediction scores of the selected four peptide of MTA1 to MHC-I supertypes. Table S2 . MHC peptide binding predictions for MTA1 (the selected four peptide, P22, P57, P109 and P129) to HLA-DRB1 using NetMHCIIpan-3.0. 
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